.png)
U.S. PORTFOLIO (AVAILABLE FOR GLOBAL OUT-LICENSING)
Current Product Portfolio – Available for Global Licensing
Solis Pharmaceuticals directly commercializes its product portfolio within the United States. For international markets outside the U.S., we are actively seeking experienced regional partners and distributors for product licensing, distribution, and commercialization. We welcome collaboration with partners who have strong local regulatory expertise, established distribution networks, and proven market presence.
Sr No | Product Name | Type | Weight |
|---|---|---|---|
Cilostazol | Tablet | 50mg | |
Cilostazol | Tablet | 100mg | |
Dapsone | Tablet | 25 mg | |
Dapsone | Tablet | 25 mg | |
Dapsone | Tablet | 100 mg | |
Dapsone | Tablet | 100 mg | |
Fluoxetine
Hydrochloride | Oral Solution | 20 mg / 5 mL | |
Fluoxetine
Hydrochloride | Oral Solution | 20 mg / 5 mL | |
Hydrocodone Bitartrate & Homatropine Methylbromide | Oral Solution | 5 mg / 1.5 mg
per 5 mL | |
Lidocaine
Hydrochloride | Injection,USP | 50 mg / 5 mL
(1%) | |
Lidocaine
Hydrochloride | Injection,USP | 100 mg / 5 mL
(2%) | |
Morphine Sulfate | Oral Solution | 10 mg / 5 mL | |
Morphine Sulfate | Oral Solution | 10 mg / 5 mL | |
Morphine Sulfate | Oral Solution | 20 mg / 5 mL | |
Morphine Sulfate | Oral Solution | 20 mg / 5 mL | |
Morphine Sulfate | Oral Solution | 100 mg / 5 mL | |
Morphine Sulfate | Oral Solution | 100 mg / 5 mL | |
Oxycodone Hydrochloride & Acetaminophen | Oral Solution | 5 mg / 325 mg
per 5 mL | |
Oxycodone Hydrochloride & Acetaminophen | Oral Solution | 5 mg / 325 mg
per 5 mL | |
Oxycodone Hydrochloride & Acetaminophen | Oral Solution | 5 mg / 325 mg
per 5 mL | |
Piroxicam | Capsule | 10 mg | |
Piroxicam | Capsule | 20 mg | |
Piroxicam | Capsule | 20 mg | |
Polyethylene Glycol 3350, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride | Powder for Oral Solution | 420 g / 1.48 g / 5.72 g / 11.2 g | |
Theophylline (Elixophyllin) | Oral Elixir / Solution | 80 mg / 15 mL | |
Theophylline (Elixophyllin) | Oral Elixir / Solution | 80 mg / 15 mL |
PRODUCTS OF INTEREST
Targeted U.S. Portfolio Acquisitions & In-Licensing
Solis is actively expanding its U.S. footprint through the acquisition and in-licensing of FDA-approved ANDA products. If you have these or additional assets available for partnership, connect with us for an immediate commercial evaluation.
Number | Product Name |
|---|---|
1 | Brimonidine Tartrate Solution/Drops 0.025% |
2 | Brimonidine Tartrate Solution/Drops 0.025% |
3 | Cefixime For Suspension 500mg/5mL |
4 | Clozapine Suspension 50mg/mL |
5 | Dexamethasone; Tobramycin Suspension/Drops 0.05%;0.3% |
6 | Ketorolac Tromethamine Solution/Drops 0.45% |
7 | Latanoprost Emulsion 0.005% |
8 | Latanoprostene Bunod Solution/Drops 0.024% |
9 | Omaveloxolone Capsule 50mg |
10 | Prednisolone Acetate Suspension Eq 15mg Base/5mL |
11 | Prednisolone Acetate Suspension Eq 5mg Base/5mL |
12 | Riluzole Suspension 50mg/10mL |
13 | Risedronate Sodium Tablet, Delayed Release 35mg |
14 | Risperidone For Suspension, Extended Release 90mg |
15 | Selumetinib Sulfate Capsule Eq 10mg Base |
16 | Triamcinolone Acetonide Injectable 40mg/mL |
Partner with Us
Business Development :
For licensing, acquisitions, and partnerships: bd@solispharmaceuticalsinc.com
​
General Inquiries:
For corporate information and general questions: info@solispharmaceuticalsinc.com
